The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the SKYLINE 102 and SKYLINE 103 trials, which showed that Alyftrek matched ...
The biotech has many more tricks up its sleeves. It recently earned approval for its next-gen cystic fibrosis (CF) therapy, Alyftrek. Vertex has a monopoly in the CF drug market. Alyftrek is yet ...
which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta. Vertex has won two cystic fibrosis approvals from the FDA, but the agency ...